Oura Targets $16B Nasdaq Listing in September

Finnish smart-ring maker Oura Health Oy seeks up to $3 billion in a September Nasdaq IPO that values the AI health platform at more than $16 billion.

Oura is targeting a valuation above $16 billion, a roughly 45% premium over its $11 billion Series E price set in October 2025.
Goldman Sachs, Morgan Stanley, and JPMorgan are co-leading an offering that could raise as much as $3 billion on the Nasdaq exchange.
Revenue doubled to $1 billion in 2025 and is projected at $1.5 billion or more for 2026, underpinned by more than five million paid members.

Lead

Oura Health Oy, the Helsinki-based maker of the Oura Ring, is targeting a September 2026 debut on the Nasdaq that would value the company at more than $16 billion and raise as much as $3 billion, positioning the offering as one of the year's defining technology listings. Goldman Sachs (GS), Morgan Stanley (MS), and JPMorgan Chase (JPM) -- joined by Allen & Co. and Jefferies -- are managing the deal after Oura filed its S-1 registration statement confidentially with the U.S. Securities and Exchange Commission in May 2026. The company is framing itself not as a consumer hardware brand but as an AI-powered health intelligence platform, a positioning choice central to the valuation argument it will carry into the roadshow.

Why Is Oura Worth Nearly $16 Billion?

A rapid revenue ramp underpins the premium. Oura generated $500 million in 2024, doubled that figure to $1 billion in 2025, and projects $1.5 billion or more for 2026 -- a threefold increase in two years. Paid memberships exceed five million, and cumulative ring sales have surpassed 5.5 million units. At $16 billion, the implied multiple represents a roughly 45% premium over the $11 billion valuation assigned during Oura's $875 million Series E round in October 2025, a mark-up that reflects both the revenue trajectory and a broader willingness among institutional buyers to apply software-style multiples to companies with defensible recurring subscription streams. Oura commands an estimated 74% share of the global smart ring market, a dominance that supports subscription pricing power and positions the company's data assets as a durable competitive moat.

What Makes Oura an AI Investment Case?

Oura's listing thesis rests on reframing its hardware as the entry point for an AI health data network. The company's proprietary Readiness Score synthesizes continuous biometric inputs -- heart rate variability, skin temperature, respiratory rate, and sleep architecture -- into a single daily metric, a design that prioritizes behavioral engagement over raw data access. The Oura Ring 5, launched in May 2026 as the world's smallest smart ring, added blood pressure trend monitoring and nighttime breathing analysis, extending the company's clinical adjacency story and broadening its addressable market toward preventive health management. Each additional enrolled member, the argument runs, improves the underlying model -- a data-network dynamic familiar to investors evaluating ai stocks and AI platform businesses more broadly, though unusual in wearables. That framing is intended to justify valuation multiples in line with software companies rather than consumer electronics peers.

How Does Oura Stack Up Against Samsung and Whoop?

Samsung (SSNLF) challenged Oura's subscription model with the Galaxy Ring, priced at $399 with no recurring fee and deep integration into the Samsung Health ecosystem. Samsung has yet to follow up the original device; the Galaxy Ring 2 has been pushed to early 2027, giving Oura a near-term window to extend its feature lead and deepen member relationships ahead of a more capable competitor re-entry. Whoop, a Boston-based rival, raised $575 million at a $10.1 billion valuation and reported more than $1 billion in bookings in 2025, with approximately 2.5 million members -- roughly half Oura's enrolled base. Whoop is itself pursuing a public listing, a parallel process that adds competitive framing to Oura's roadshow but also validates institutional appetite for the health-wearable category at scale.

Outlook

Oura's September target remains contingent on market conditions, and the final valuation range and deal size will be set closer to the pricing date. If completed above $16 billion, the offering would rank among the largest technology IPOs of 2026 and establish a public benchmark for health-wearable companies pursuing software multiples. Revenue growth, a defensible market share position, and the Ring 5 hardware cycle give the company credible metrics to sustain its AI platform narrative through the roadshow process. The outcome will likely shape the timeline and ambition of Whoop's own listing plans and set expectations for a fourth-quarter health-technology pipeline that has been building since early in the year.